Ligand Pharmaceuticals | LGND - Operating Expenses


Ligand Pharmaceuticals reported $8.29M in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
Amgen USD 5.13B 1.39B Sep/2025
Arrowhead Research USD 212.37M 19.05M Sep/2025
Baxter International USD 2.63B 95.8M Sep/2025
Bristol-Myers Squibb USD 18.55B 10.06B Sep/2025
Eli Lilly USD 9.21B 677.8M Sep/2025
Gilead Sciences USD 4.26B 95M Sep/2025
GlaxoSmithKline GBP 5.76B 203M Sep/2025
Glaxosmithkline GBP 7.77B 2.22B Sep/2025
Insmed USD 403.69M 42.4M Sep/2025
Ionis Pharmaceuticals USD 316.9M 4.69M Sep/2025
Ligand Pharmaceuticals USD 8.29M 32.17M Sep/2025
MacroGenics USD 67M 8M Sep/2025
Merck USD 10.72B 1.28B Sep/2025
Pacira USD 166.36M 4.5M Sep/2025
Pfizer USD 92.8B 82.47B Sep/2025
Veracyte USD 108.76M 7.09M Sep/2025